89 results about "Cycloalliin" patented technology

A robust compound is provided having the formula: wherein Y1, Y2, Y3 and Y4 are oxidation resistant groups which are the same or different and which form 5- or 6-membered rings with a metal, M, when bound to D. D is a metal complexing donor atom, O or N. Each X is a position for addition of a substituent and, when D is N, each position is (i) not occupied such that a double bond is formed between D and an atom adjacent to D, or (ii) is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, alkoxy, phenoxy, halogen, halogenated alkyl, halogenated aryl, halogenated alkenyl, halogenated alkynyl, perhaloalkyl, perhaloaryl, a substituted or unsubstituted cycloalkyl ring, a substituted or unsubstituted cycloalkenyl ring, a substituted or unsubstituted saturated heterocyclic ring, a substituted or unsubstituted unsaturated heterocyclic ring, and at least one X is hydrogen, and when D is O, the position is not occupied.

A composition of (a) a fluoropolymer having interpolymerized units derived from a nitrogen-containing cure site monomer; and (b) a nonfluorinated catalyst composition that includes a compound having the general formula: {RA}⁽⁻⁾{QR′_k}⁽⁺⁾ or in certain cases the precursors thereof, wherein R is hydrogen, an alkyl, alkenyl, cycloalkyl, cycloalkenyl, aryl or aralkyl, A is an acid- or acid-derivative anion, Q is phosphorous, sulfur, nitrogen, arsenic, or antimony, and each R′ is hydrogen or an alkyl, aryl, aralkyl, or alkenyl group, k is the valence of Q; and optionally (c) an alcohol of the formula R²—OH, wherein R² is an alkyl group which can be partially fluorinated. Also provided are a method of making a fluoropolymer, a method of increasing induction time, and fluoropolymer articles containing curable or cured fluoropolymer compositions.

The present invention provides a silicon compound represented by Formula (1) and a polymer obtained by using the same, and this makes it possible not only to obtain an organic-inorganic composite material having a distinct structure but also to control the structure of the above polymer as a molecular aggregate.

wherein R¹ is a group independently selected from hydrogen, alkyl having a carbon atom number of 1 to 40, substituted or non-substituted aryl and substituted or non-substituted arylalkyl; in this alkyl having a carbon atom number of 1 to 40, optional hydrogens may be substituted with fluorine, and optional —CH₂— may be substituted with —O—, —CH═CH—, cycloalkylene or cycloalkenylene; in alkylene in this arylalkyl, optional hydrogens may be substituted with fluorine, and optional —CH₂— may be substituted with —O— or —CH═CH—; and A¹ is a group having an α-haloester bond.

An m-terphenyl derivative has a structure of formula (I) or (II):

wherein A and B are five-membered heterocyclic compounds containing nitrogen, each of substituents R, R₁ and R₂ is a member independently selected from the group consisting of H, halo, cyano, trifluoromethyl, amino, C₁-C₁₀ alkyl, C₂-C₁₀ alkenyl, C₂-C₁₀ alkynyl, C₃-C₂₀ cycloalkyl, C₃-C₂₀ cycloalkenyl, C₁-C₂₀ heterocycloalkyl, C₁-C₂₀ heterocycloalkenyl, aryl and heteroaryl. The compound of the present invention may have advantages in good electron affinity, low HOMO and thereby achieving hole blocking and may be used for electron transport material and/or electron injection material.

Disclosed is a novel compound that acts as an antagonist for P2X3 and/or P2X2/3 receptors. Also disclosed is a pharmaceutical composition that acts as an antagonist for P2X3 and/or P2X2/3 receptors, said composition containing: a compound represented by formula (I), a pharmacologically permitted salt thereof, or a solvate of either. In the formula, ring A represents a substituted or unsubstituted five-to-seven-membered cycloalkane, a substituted or unsubstituted five-to-seven-membered cycloalkene, or the like; C represents a carbon atom; -X- represents -N(R16)- or the like; R16 represents hydrogen, a substituted or unsubstituted alkyl, or the like; R7 represents a substituted or unsubstituted five- or six-membered heteroaryl or a substituted or unsubstituted six-to-ten-membered aryl; each of Q1 and Q2 independently represents a carbon atom or a nitrogen atom; -L- represents -O-, -S-, or the like; R6 represents a substituted or unsubstituted cycloalkyl, a substituted or unsubstituted cycloalkenyl, or the like; and R2 represents hydrogen, hydroxyl, or the like.

Isoxazoles of formula (A) or (B) are inhibitors of HSP90 activity, and useful for treatment of, for example cancers: (A), (B) wherein R₁, is a group of formula (IA): —Ar¹-(Alk¹)p-(Z)_r-(Alk²)_s-Q, wherein in any compatible combination Ar¹ is an optionally substituted aryl or heteroaryl radical, Alk¹ and Alk² are optionally substituted divalent C₁-C₆ alkylene or C₂-C₆ alkenylene radicals, p, r and s are independently 0 or 1, Z is -0-, —S—, —(C═O)—, —(C═S)—, —SO₂—, —C(═O)O—, —C(═O)NR^A—, —C(═S)NR^A—, —SO₂NR^A—, —NR^AC(═O)—, —NR^ASO₂— or —NR^A— wherein R^A is hydrogen or C₁-C₆ alkyl, and Q is hydrogen or an optionally substituted carbocyclic or heterocyclic radical; R₂ is (i) a group of formula (IA) above or (ii) a carboxamide radical; or (iii) a non aromatic carbocyclic or heterocyclic ring wherein a ring carbon is optionally substituted, and/or a ring nitrogen is optionally substituted by a group of formula -(Alk¹)p-(Z)_r-(Alk²)_s-Q wherein Q, Alk¹, Alk², Z, p, r and s are as defined above in relation to group (IA); and R₃ is hydrogen, optionally substituted cycloalkyl, cycloalkenyl, C₁-C₆ alkyl, C₁-C₆ alkenyl, or C₁-C₆ alkynyl; or a carboxyl, carboxamide, or carboxyl ester group.

The invention relates to an extract method of Chinese traditional medicinal compound rhizoma coptidis alexipharmic soup active part and an application of the active part in preparing medicament resisting vascular dementia. The extract method disclosed by the invention adopts industrialized separating and refining technologies, such as microporous membrane and macroporous resin absorption, greatly decreases cream yield of the preparation, maximally retains effective components, improves transforming rate of effective components in raw materials and purity of effective components in the preparation. The extracted active part comprises three kinds of known chemical components: alkaloids, flavonoid glycosides and iridoid glycosides respectively, and has a vascular dementia resisting function.

A process for extracting the iridoid glycoside from common lamiophlomis herb includes reflux extracting in alcohol solution, macroreticular resin adsorpotion, and separation. Said iridoid glycoside can be used as the active staltic component.

The invention discloses a total effective part extractive of morinda officinalis, a preparation method and application thereof in medicaments for treating snoring, and the total effective part comprises the following components in percentage by weight: 50-90 percent of morinda officinalis total polysaccharide, 2-5 percent of morinda officinalis total anthraquinone, 5-30 percent of morinda officinalis total iridoids and the like. The preparation method comprises the following steps of: drying the morinda officinalis, and crushing into 10-100 meshes; heating with water for reflux extraction; processing the extract by using a weak base anion exchange resin column, collecting the cross-flow liquid and water eluent, and condensing and drying to obtain the total polysaccharide; carrying out reflux extraction on the dregs of decoction with petroleum ether or 6# extraction solvent oil or other organic solvents with polarity similar to that of the dregs, and removing low-polarity components, such as essential oil and the like; heating the residual dregs with ethanol water with a certain concentration for reflux extraction, and condensing the extract to prepare the total anthraquinone and total iridoids; and then merging the three components, and drying to obtain the total effective part extractive of morinda officinalis. The product of the invention is used for treating snoring (also called as Sleep apnea syndrome (SAS)), and has the advantages of quick and remarkable curative effect, no toxic or side effect, low price, convenient use and the like.

The invention discloses an effective part of spreading hedyotis herb and a preparation method thereof. The preparation method comprises the following steps of: purifying the effective part of the spreading hedyotis herb, determining the content of total iridoid glycoside and 6-O-p-coumaroyl scandoside methyl ester in the effective part of the spreading hedyotis herb, and further defining effective anti-tumor ingredients in the effective part; the preparation method is beneficial to increase of the stability of products; meanwhile, mice anti-tumor experiments and the contrast between the effective part and a clinically commonly-used anti-tumor medicine, namely, cyclophosphamide, show that the effective part of the spreading hedyotis herb has an obvious anti-tumor effect.

A compound of the formula (I):

wherein

• • R is selected from the group consisting of H, alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl and acyl, each of which may be optionally substituted;
  • R¹ is an organic moiety that is capable of being converted into a charged group;
  • each X and Y is independently selected from the group consisting of H, halogen, —CN, —NO₂, —CF₃, —OCF₃, alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, heteroalkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, heteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl, arylalkenyl, cycloalkylheteroalkyl, arylheteroalkyl, heterocycloalkylheteroalkyl, heteroarylheteroalkyl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, alkoxyaryl, alkenyloxy, alkynyloxy, cycloalkyloxy, heterocycloalkyloxy, aryloxy, heteroaryloxy, arylalkyloxy, phenoxy, benzyloxy, amino, alkylamino, aminoalkyl, acylamino, arylamino, sulfonylamino, sulfinylamino, —COOH, —COR², —COOR², —CONHR², —NHCOR², —NHCOOR², —NHCONHR², C(═NOH)R², alkoxycarbonyl, alkylaminocarbonyl, sulfonyl, alkylsulfonyl, alkylsulfinyl, arylsulfonyl, arylsulfinyl, aminosulfonyl, SR² and acyl, each of which may be optionally substituted;
  • each R² is independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, haloalkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl, heteroarylalkyl, and acyl, each of which may be optionally substituted;
  • m is an integer selected from the group consisting of 0, 1, 2, 3, 4 and 5;
  • p is an integer selected from 0, 1, 2 and 3;

or a pharmaceutically acceptable salt or prodrug thereof.

To provide cytokine production inhibitors useful as preventive or therapeutic medicines for diseases accompanied by hyperactivated immune functions.

A cytokine production inhibitor containing, as an active ingredient, a thioamide compound represented by the formula (I) or a salt thereof:

• wherein A is N, NO, C—NO₂ or C—CN; Hal is a halogen; M¹ is alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, heterocyclyl, amino, O, S, SO or SO₂; M² is amino, O, S or a single bond; R¹ is a halogen, alkyl or the like; each of R², R³, R⁴ and R⁵ is independently H, alkyl or the like; R⁶ is a halogen, alkyl or the like; Cy is cycloalkyl, cycloalkenyl, aryl or heterocyclyl; each of k, p and q is independently an integer of from 0 to 3; and r is an integer of from 0 to 5.

The invention provides a method for simultaneously preparing six iridoid glycoside components from jasmine flowers efficiently and rapidly. The method comprises the steps that jasmine fruit alcohol extracts are subjected to macroporous resin coarse separation, reverse phase intermediate-pressure preparation solution liquid chromatogram enriched flow separation and reverse phase high-pressure separation and purification, and the six monomer compounds with the purity higher than 95% or above can be obtained. The method can enlarge the laboratory separation scale and improve the purifying efficiency; the preparation technology is simple, the cost is low, the extraction efficiency is high, more importantly, samples are not wasted, and the crystallization purity is high.

A compound useful as an AMPK-activating agent is provided. A compound represented by formula (I) (wherein X represents a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted alkynyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted cycloalkenyl group or a substituted or unsubstituted heterocyclyl group; R1 represents a hydrogen atom, a halogen atom, a cyano group, a nitro group, a carboxy group, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted acyl group, a substituted or unsubstituted carbamoyl group, a substituted or unsubstituted alkylthio group, a substituted or unsubstituted alkylsulfinyl group, a substituted or unsubstituted alkylsulfonyl group or a substituted or unsubstituted alkyloxycarbonyl group; R2 represents a halogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted alkynyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted cycloalkenyl group, a substituted or unsubstituted heterocyclyl group or the like; R3 represents a halogen atom, a hydroxy group, a cyano group, a nitro group, a carboxy group, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted alkynyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted cycloalkenyl group, a substituted or unsubstituted heterocyclyl group or the like; and R4 represents a hydrogen atom, a halogen atom, a hydroxy group, a cyano group, a nitro group, a carboxy group, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted alkynyl group or the like) or a pharmaceutically acceptable salt thereof.

The invention belongs to the technical field of medicine production research development, and relates to isolation and identification as well as application of volatile oil elements of Parasenecio firmus leaf. The isolation and identification of the volatile oil elements of the Parasenecio firmus leaf are realized by the following steps of: weighing dried Parasenecio firmus leaf, and extracting ultrasonically by a water steam distillation method to obtain the volatile oil; and analyzing the obtain volatile oil by utilizing a 6890/5973N gas chromatograph-mass spectrometer. The obtain volatile oil mainly comprises the following chemical elements in proportion: 18.98% of n-palmitic acid, 9.89% of 1-tridecylene, 8.05% of caryophyllene epoxide, 6.04% of (S)-undeca-cycloolefin, 3.84% of 9,12,15-octadecatrienoic acid, 2.97% of (-)-spathulenol, 2.83% of kaurene and 2.12% of caryophyllene. The volatile oil is used for preparing pharmaceutical preparation capable of restraining escherichia coli, streptococcus, Salmonella, Pasteurella and staphylococcus aureus.

A composition of a fluoropolymer comprising interpolymerized units of nitrogen-containing cure site monomer and a catalyst comprising a compound having the formula:

wherein HA is an acid, each R₁, R₂, and R₃ is independently a C₁-C₂₀ alkyl group, which may be cyclic or heterocyclic, or R_f(CH₂)_n— wherein R_f is a C₁-C₈ linear or branched and at least partially fluorinated, and x is 1 to 4, and one R group may be a bond to another R group such that the nitrogen is bonded to or part of an alkenyl, cycloalkenyl, or aromatic group. This may further comprise a catalyst composition comprising a compound of the formula R¹C(OR²)═NH, and salts thereof, where each R¹ and R² is, independently, a substituted or unsubstituted alkyl, aryl, aralkyl, alkenyl, cycloalkyl, or cycloalkenyl. Also provided are a method of making a fluoropolymer composition and articles prepared from the compositions.

Disclosed is a novel fused bicyclic compound [I] shown below, which has affinity for a mineralcorticoid receptor (MR) and is useful as an anti-hypertensive agent or the like. Specifically disclosed is a compound represented by the formula [I] or a pharmacologically acceptable salt thereof. [I] wherein the ring A represents a benzene ring which is fused with the adjacent heterocyclic 6-membered ring and has a substituent R1, and which may have a substituent other than R1; R1 represents an alkylsulfonylamino group or the like; R2 and R3 (a) independently represent a hydrogen, an alkyl or a substituted or unsubstituted aryl, (b) together form an oxo, or (c) together with the adjacent carbon atom, form a cycloalkyl; X represents =N-, =C(R4)- or -CH(R4)-; R4 represents (a) a hydrogen, (b) a cyano, (c) a halogen, (d) an alkyl, (e) an alkenyl, (f) a cycloalkyl, (g) an alkanoyl, (h) a carbamoyl or (i) a cycloalkenyl; Ar represents a substituted or unsubstituted aromatic cyclic group; and a dotted line means the presence or absence of a double bond.

Provided is a compound useful as an AMPK activator. A compound represented by formula (wherein R4 represents a hydrogen atom or a substituted or unsubstituted alkyl group; R1, R2 and R3 independently represent a hydrogen atom, a halogen atom, a hydroxy group, a cyano group, a nitro group, a carboxy group, a substituted or unsubstituted alkyl group, or the like, wherein a case in which R1, R2 and R3 represent a hydrogen atom simultaneously is excluded; X represents a single bond, -S-, -O-, -NR5-, -C(=O)-, or the like; R5 represents a hydrogen atom, or a substituted or unsubstituted alkyl group; and Y represents a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted cycloalkenyl group, a substituted or unsubstituted heterocyclyl group, or the like), or a pharmaceutically acceptable salt thereof.